Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniel Dingfeng Jiang"'
Autor:
Toby A. Eyre, Hande H. Tuncer, Rajesh Kamalakar, Daniel Dingfeng Jiang, John N. Allan, Paul M. Barr, Anthony R. Mato, Danielle M. Brander, Nnadozie Emechebe, Lindsey E. Roeker, Matthew S. Davids, Chaitra S. Ujjani, Dandan Zheng, Beenish S Manzoor, Rebecca Burne, Annie Guerin, German Pena, Kavita Sail, Barbara Eichhorst, Jennifer R. Brown, Rajat Bannerji, Irina Pivneva, Alan P Skarbnik, Simon Sharmokh
Publikováno v:
Blood. 136:19-22
Introduction: Venetoclax has demonstrated deep responses and sustained progression-free survival and is well tolerated in patients (pts) with previously untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (C
Autor:
John Pesko, Suzanne R. Fanning, Jay Courtright, David Andorsky, Habte A. Yimer, Kathryn S. Kolibaba, Sudhir Manda, Jason M. Melear, Jeff P. Sharman, Daniel Dingfeng Jiang, Ian W. Flinn, Miguel Islas-Ohlmayer, Suman Kambhampati, Tamas Vizkelety, John M. Burke, Simon Sharmokh, Bertrand Anz
Publikováno v:
Blood. 136:4-5
Background: Venetoclax (VEN), a B-cell lymphoma 2 inhibitor, is an oral agent with demonstrated efficacy in patients (pts) with chronic lymphocytic leukemia (CLL). VEN treatment induces rapid tumor reduction, posing a risk for tumor lysis syndrome (T
Autor:
Beenish S Manzoor, George A. Follows, Paul M. Barr, Maryam Sarraf Yazdy, Irina Pivneva, Daniel Dingfeng Jiang, Chaitra S. Ujjani, Bruce D. Cheson, Anthony R. Mato, Toby A. Eyre, Mazyar Shadman, Jennifer R. Brown, German Pena, Danielle M. Brander, Jacqueline Nielsen, John N. Allan, Simon Sharmokh, James M. Pauff, Nicole Lamanna, Rajat Bannerji, Lindsey E. Roeker, Thomas S. Marshall, William G. Wierda, Hande H. Tuncer, Barbara Eichhorst, Kavita Sail, Anna Schuh, Brian T. Hill, Alan P Skarbnik, Stephen J. Schuster
Publikováno v:
Blood. 134:1756-1756
BACKGROUND Novel agents have changed the treatment landscape in chronic lymphocytic leukemia (CLL), however little has been reported about real-world treatment sequence patterns and associated outcomes post-introduction of novel agents. Studies have
Autor:
Nicole Lamanna, Anna Schuh, Bruce D. Cheson, Chaitra S. Ujjani, George A. Follows, James M. Pauff, Paul M. Barr, Annie Guerin, Nnadozie Emechebe, Jennifer R. Brown, Toby A. Eyre, Rajat Bannerji, Rajesh Kamalakar, Daniel Dingfeng Jiang, John N. Allan, Simon Sharmokh, Jacqueline Nielsen, Anthony R. Mato, Thomas S. Marshall, Hande H. Tuncer, Mazyar Shadman, German Pena, Maryam Sarraf Yazdy, Barbara Eichhorst, William G. Wierda, Kavita Sail, Lindsey E. Roeker, Irina Pivneva, Beenish S Manzoor, Brian T. Hill, Alan P Skarbnik, Stephen J. Schuster, Danielle M. Brander
Publikováno v:
Blood. 134:3048-3048
BACKGROUND The recent approval of novel agents (NAs) has changed the treatment landscape in chronic lymphocytic leukemia (CLL), however, there remains uncertainty regarding treatment discontinuation patterns in real-world (RW) settings. This study as